Skip navigation


Kidney gene panel

Renasight is a test to determine if there is a genetic cause for an individual’s kidney disease or if there is an increased hereditary risk due to family history. The test uses a blood or saliva sample to test 385 genes associated with chronic kidney disease (CKD). Results are available in approximately 3 weeks.

See more. Know more. With Renasight.

  • Leverages next-generation sequencing and other methodologies on more than 380 genes associated with kidney disease
  • Identifies autosomal dominant, autosomal recessive, and X-linked disorders
  • Reports out pathogenic and likely pathogenic variants that were selected by genetic experts to provide actionable information
  • > 99% detection rates across the genes screened1


Search a gene or condition

Built on evidence

Built on evidence

A recent New England Journal of Medicine publication assessing the incidence of genetic disease in kidney disease population found ~1 in 10 patients have a genetic diagnosis.2

Pinpoint and plan

Testing at the molecular level offers deeper insights to help deliver individualized patient care. In 89% of patients with kidney disease, a genetic diagnosis had implications for clinical management.2

Pinpoint and plan

Integrate Renasight for better patient care


Gain prognostic insight


Identify an etiology for patients with unknown cause of their kidney disease


Prescribe targeted therapies


Refer patients for extra-renal features


Test family members and offer genetic counseling


Enroll patients in clinical trials

Learn more about Renasight: Clinician brochure

Commitment to affordability

We welcome all insurance plans and provide affordable testing through a variety of payment methods. Natera offers discounted self-pay pricing and financial assistance through our compassionate care program.

The Natera team is here to help you with any billing or reimbursement questions at +1 650.425.4005.

Commitment to affordability

Request more information about Renasight

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time.


1Natera data on file

2Groopman EE, Marasa M, Cameron-Christie S et al. Diagnostic utility of exome sequencing for kidney disease. NEJM. 2018;doi:10.1056.

icon-angle icon-bars icon-times